"Androgen Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
Descriptor ID |
D000726
|
MeSH Number(s) |
D06.347.065 D27.505.696.399.450.065
|
Concept/Terms |
Anti-Androgen Effect- Anti-Androgen Effect
- Anti Androgen Effect
- Effect, Anti-Androgen
- Antiandrogen Effect
- Effect, Antiandrogen
- Antiandrogen Effects
- Effects, Antiandrogen
- Anti-Androgen Effects
- Anti Androgen Effects
- Effects, Anti-Androgen
|
Below are MeSH descriptors whose meaning is more general than "Androgen Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Androgen Antagonists".
This graph shows the total number of publications written about "Androgen Antagonists" by people in this website by year, and whether "Androgen Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
1997 | 0 | 1 | 1 |
1999 | 1 | 0 | 1 |
2001 | 1 | 0 | 1 |
2002 | 1 | 0 | 1 |
2003 | 3 | 0 | 3 |
2004 | 1 | 0 | 1 |
2005 | 3 | 2 | 5 |
2006 | 1 | 0 | 1 |
2007 | 3 | 2 | 5 |
2008 | 1 | 1 | 2 |
2009 | 1 | 5 | 6 |
2010 | 2 | 4 | 6 |
2011 | 1 | 0 | 1 |
2012 | 2 | 1 | 3 |
2013 | 5 | 2 | 7 |
2014 | 4 | 4 | 8 |
2015 | 1 | 1 | 2 |
2016 | 0 | 2 | 2 |
2017 | 8 | 1 | 9 |
2018 | 4 | 3 | 7 |
2019 | 1 | 0 | 1 |
2020 | 3 | 1 | 4 |
2021 | 1 | 9 | 10 |
2022 | 1 | 7 | 8 |
2023 | 2 | 11 | 13 |
To return to the timeline,
click here.
Below are the most recent publications written about "Androgen Antagonists" by people in Profiles.
-
Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis. Clin Cancer Res. 2023 12 01; 29(23):4930-4940.
-
Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system. Cancer. 2023 10 15; 129(20):3326-3333.
-
Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies. Eur Urol. 2023 09; 84(3):331-340.
-
BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade. Mol Cancer Ther. 2023 06 01; 22(6):751-764.
-
Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer. Clin Cancer Res. 2023 05 15; 29(10):1952-1968.
-
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. Eur Urol. 2023 08; 84(2):229-241.
-
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial. Eur Urol. 2023 08; 84(2):156-163.
-
Emerging treatment options for prostate cancer. Expert Rev Anticancer Ther. 2023 06; 23(6):625-631.
-
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2023 10 01; 117(2):370-377.
-
ACR Appropriateness Criteria® Post-Treatment Follow-up of Prostate Cancer: 2022 Update. J Am Coll Radiol. 2023 05; 20(5S):S164-S186.